1. Home
  2. CIK vs SPRO Comparison

CIK vs SPRO Comparison

Compare CIK & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Credit Suisse Asset Management Income Fund Inc.

CIK

Credit Suisse Asset Management Income Fund Inc.

HOLD

Current Price

$2.48

Market Cap

136.1M

Sector

Finance

ML Signal

HOLD

Logo Spero Therapeutics Inc.

SPRO

Spero Therapeutics Inc.

HOLD

Current Price

$2.12

Market Cap

156.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CIK
SPRO
Founded
N/A
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
136.1M
156.3M
IPO Year
1995
2017

Fundamental Metrics

Financial Performance
Metric
CIK
SPRO
Price
$2.48
$2.12
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
551.8K
1.6M
Earning Date
01-01-0001
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
111.81
EPS
N/A
N/A
Revenue
N/A
$66,802,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$300.00
P/E Ratio
N/A
N/A
Revenue Growth
N/A
39.24
52 Week Low
$2.43
$1.80
52 Week High
$3.01
$3.08

Technical Indicators

Market Signals
Indicator
CIK
SPRO
Relative Strength Index (RSI) 47.92 38.15
Support Level $2.44 $1.93
Resistance Level $2.57 $2.45
Average True Range (ATR) 0.03 0.11
MACD 0.00 -0.00
Stochastic Oscillator 64.29 29.60

Price Performance

Historical Comparison
CIK
SPRO

About CIK Credit Suisse Asset Management Income Fund Inc.

Credit Suisse Asset Mgmt Income Fund Inc is a closed-end management investment company. The investment objective of the fund is to provide current income consistent with the preservation of capital. UBS Asset Management serves as an investment adviser for the fund. Asset Management offers a wide range of investment products and functions across asset classes and investment styles. The division manages various regional portfolios, mutual funds, and other investment vehicles for governments, institutions, corporations and individuals.

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

Share on Social Networks: